Under the terms of the deal, Boehringer has the exclusive option to license Sosei's GPR52 agonistsGPR52 agonists, a novel G protein-coupled receptor target, following the completion of Sosei’s ongoing phase 1 and subsequent phase 1b trial and phase 2 enabling activities with HTL0048149, a first-in-class GPR52 agonistGPR52 agonist. Sosei Heptares will sponsor the trials until the option exercise, estimated in 2025.
According to Boehringer, the development of a new schizophrenia treatment targeting GPR52 has the potential to address all three aspects of schizophrenia — ‘positive’ symptoms (psychosis, delusions and hallucinations), ‘negative’ symptoms (social withdrawal and apathy) and cognitive symptoms (attention, planning and memory deficits).
In the deal, Sosei will receive an upfront payment of $27.3 million (€25 million) from Boehringer, and is eligible for an option exercise payment of $65.6 million (€60 million) and further development, regulatory and commercialization milestone payments totaling up to $732.7 million (€670 million).
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.